BioSpace News Archive

Epileptic Seizures Treatment Market Size US$ 1.8 Billion by 2030

The global epileptic seizures treatment market is expected to grow at a moderate CAGR of ~4% during the forecast period.

August 5, 2022
·
10 min read
Hyperthermia Cancer Treatment Market Size to Reach US$ 266 Mn by 2030

According to Report Study, the hyperthermia cancer treatment market is predicted to reach US$ 266 Mn by the end of 2030.

August 5, 2022
·
11 min read
Multiplex Detection Immunoassays Market Size US$ 3.65 Bn by 2030

At the back of these factors, along with a surge in the number of research and development activities, the global multiplex detection immunoassays market is on the course to surpass US$ 3.65 Bn mark by the end of 2030.

August 5, 2022
·
12 min read
Newborn Screening Market Size to Reach US$ 3.3 Bn by 2030

The newborn screening market is expected to advance at a robust CAGR of 11% during the forecast period.

August 5, 2022
·
10 min read
Positron Emission Tomography [PET] Scanners Market Size US$ 1.2 Bn by 2030

The global positron emission tomography (PET) scanners market was valued at US$ 915.5 Mn in 2022 and is anticipated to expand at a CAGR of 3% from 2020 to 2030.

August 5, 2022
·
11 min read
Radiation Proctitis Market Size to Reach US$ 748.5 Mn by 2030

The radiation proctitis market is projected to register a favorable CAGR of ~7% during the assessment period, owing to a high prevalence of radiation toxicity.

August 5, 2022
·
10 min read
Venous Procedure Devices Market Size to Reach US$ 3.4 Billion by 2030

The global venous procedure devices market was valued at ~US$ 2 Bn in 2022 and it is anticipated to expand at a CAGR of 6% from 2022 to 2030.

August 5, 2022
·
10 min read
Policy

FDA Infant Formula Update: August 5, 2022

The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities.

August 5, 2022
·
4 min read
FDA

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer.

August 5, 2022
·
4 min read
Pharm Country

Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics

Todos Medical, Ltd. (OTCQB: TOMDF), today announced the first commercial patient samples have been received for its Long COVID Panel biomarker partnership between its CLIA/CAP certified lab Provista Diagnostics and Amerimmune Diagnostics.

August 5, 2022
·
8 min read